{"Content: ":"Razi Cov Pars (Persian: رازی کوو پارس) is a COVID-19 vaccine developed by the Iranian Razi Vaccine and Serum Research Institute.[1][2][3] It's the second Iranian COVID-19 vaccine reaching human trials[1] and is currently in phase III of clinical research during which it's compared to the Sinopharm BIBP vaccine.[4][5] It received emergency use authorization in Iran on 31 October 2021.[6][7] It requires three doses given day 0 (intramuscular), day 21 (intramuscular) and day 51 (intranasal spray).[3] Razi Cov Pars is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein.[2] It's planned to produce one million doses of the vaccine each month as of September 2021.[4] As of 25 November 2021, 5 millions doses have been delivered to the Iranian Ministry of Health.[8] 30 (10 µg/200µL) 30 (20 µg/200µL) 13 (sentinel) 20,564 (Sinopharm BIBP vaccine) Raz Cov Pars received emergency use authorization in Iran on 31 October 2021.[6][7] This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.","Title":"Razi Cov Pars - Wikipedia","KeyID":"11136","URL":"https://en.wikipedia.org/wiki/Razi_Cov_Pars"}